♟️ Monday 31 August 2026 Mon, 31 Aug 2026

Pure Foods Tasmania reports a modest revenue dip but boosts gross profit and margin in FY26, while statutory losses swell due to non-cash accounting adjustments and strategic realignment.

Thorney Opportunities Ltd swung to a $4.44 million loss before tax in FY2026, weighed down by unrealised investment losses, yet increased its final dividend and pressed on with share buybacks.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.

Pengana International Equities (ASX: PIA) posted a sharp 82% plunge in net profit for FY26, triggering a strategic board reshuffle and a capital management package including a special dividend and buy-back proposal.

Infotrust Ltd (ASX: ITS) reported a 9.8% rise in FY26 revenue to $64.1 million, powered by a strategic pivot to cyber security. The company exited its Cloud segment, repaid all bank debt, and acquired Catalyst Cyber to boost federal market presence, positioning for profitable growth in FY27.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

AF Legal Group Ltd reported a 30% surge in revenue to $35.9 million and a 354% increase in profit after tax attributable to owners in FY26, driven by strategic investments in technology and management restructuring.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Adslot Ltd swung to a $4.2 million profit in FY2026, buoyed by a $6 million non-cash gain from deconsolidating its troubled subsidiary. The company’s restructuring efforts trimmed costs by 28%, but revenue fell 10%.

SportsHero Limited reported a dramatic surge in revenue to AU$1.05 million for FY26, driven by new telco partnerships and the HeroPlay gaming platform launch, while losses increased 29% as the company ramped up marketing and development costs.

Maggie Beer Holdings reported a 60.8% reduction in net loss for FY26 to $9.5 million despite flat sales, driven by margin gains and cost cuts. The company appointed Chris Illman as Managing Director to lead its recovery and growth strategy.

Nimy Resources reports metallurgical tests achieving 84% gallium and up to 95% rare earth extraction at its Mons Project Block 3, underpinning proprietary processing technology and feeding into a scoping study.

AMCIL posted a $6.9 million profit for FY2026 while its portfolio returned negative 10%, underperforming the ASX 200. The company cut dividends to 4.0 cents fully franked, reshuffled holdings, and welcomed Alison Gibson as new CEO.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.

Peak Processing Limited’s FY26 results reveal a doubling loss from continuing operations to $10 million amid a $4.35 million impairment, offset partially by a $2.5 million profit from discontinued operations. The company completed an operational reset and posted its first positive EBITDA quarter in June 2026.

Salter Brothers Emerging Companies Limited (ASX:SB2) swung to a $7.9 million loss for FY26, driven by a $10.5 million investment write-down, while maintaining dividend payments and extending its share buy-back program.